Ashok Kumar Saxena1, Deepanshu Khrolia1, Geetanjali T Chilkoti1, Prakash Gyandev Gondode2, Tusha Sharma3, Gaurav Thakur3, Basu Dev Banerjee3. 1. Department of Anesthesiology and Critical Care, University College of Medical Sciences and Guru Teg Bahadur Hospital, Maharashtra, India. 2. Department of Anesthesiology and Critical Care, All India Institute of Medical Sciences, Nagpur, Maharashtra, India. 3. Department of Biochemistry, University College of Medical Sciences and GTB Hospital, University of Delhi, Delhi, India.
Abstract
OBJECTIVES: The aim of this study is to study the modulation of extracellular signal-regulated protein kinase (ERK) and tissue inhibitors of matrix metalloproteases 1 (TIMP 1) gene in patients with neuropathic pain (NP). MATERIALS AND METHODS: In the present, cross-sectional, observational study, 2 ml of venous baseline sample was withdrawn from all the patients with neuropathic (NP) or non NP (NNP) soon after their diagnosis or on their first visit to the pain clinic. A real-time quantitative polymerase chain reaction experiment was conducted to measure the mRNA expression of TIMP1 and ERK genes in blood samples. The Delta Ct, Delta Ct, and fold change analysis of both the genes were conducted between patients with NP and NNP. RESULTS: A total of 285 patients with chronic pain were assessed, out of which, 153 patients had NP and 132 had NNP. The average duration of chronic pain was 11 months for 285 patients. The mRNA expression of TIMP1 gene is significantly down regulated (2.65-fold) (P (-f. 01), and the mRNA expression level of ERK is significantly up regulated (2.03-fold) (P (-f. 01) in NP patients when compared with NNP. CONCLUSION: The mRNA expression of TIMP1 gene is significantly down regulated, and ERK is significantly up regulated in patients with NP. Further, multicentric trials with larger sample size are recommended to confirm this finding.
OBJECTIVES: The aim of this study is to study the modulation of extracellular signal-regulated protein kinase (ERK) and tissue inhibitors of matrix metalloproteases 1 (TIMP 1) gene in patients with neuropathic pain (NP). MATERIALS AND METHODS: In the present, cross-sectional, observational study, 2 ml of venous baseline sample was withdrawn from all the patients with neuropathic (NP) or non NP (NNP) soon after their diagnosis or on their first visit to the pain clinic. A real-time quantitative polymerase chain reaction experiment was conducted to measure the mRNA expression of TIMP1 and ERK genes in blood samples. The Delta Ct, Delta Ct, and fold change analysis of both the genes were conducted between patients with NP and NNP. RESULTS: A total of 285 patients with chronic pain were assessed, out of which, 153 patients had NP and 132 had NNP. The average duration of chronic pain was 11 months for 285 patients. The mRNA expression of TIMP1 gene is significantly down regulated (2.65-fold) (P (-f. 01), and the mRNA expression level of ERK is significantly up regulated (2.03-fold) (P (-f. 01) in NP patients when compared with NNP. CONCLUSION: The mRNA expression of TIMP1 gene is significantly down regulated, and ERK is significantly up regulated in patients with NP. Further, multicentric trials with larger sample size are recommended to confirm this finding.
Authors: Troels S Jensen; Ralf Baron; Maija Haanpää; Eija Kalso; John D Loeser; Andrew S C Rice; Rolf-Detlef Treede Journal: Pain Date: 2011-07-18 Impact factor: 6.961
Authors: S D Dib-Hajj; A M Rush; T R Cummins; F M Hisama; S Novella; L Tyrrell; L Marshall; S G Waxman Journal: Brain Date: 2005-06-15 Impact factor: 13.501
Authors: B Gustorff; T Dorner; R Likar; W Grisold; K Lawrence; F Schwarz; A Rieder Journal: Acta Anaesthesiol Scand Date: 2007-11-01 Impact factor: 2.105